Medicenna Therapeutics Corp. Adjustments For Unrealised Foreign Exchange Losses Gains
Medicenna Therapeutics Corp. (MDNAF) reported Adjustments For Unrealised Foreign Exchange Losses Gains of -CAD 1.07 million for the 3-month period ending 2023-03-31, per its 20-F filed 2023-06-27.
Discontinued › Income Statement › Other Income
ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains · last filed 2023-06-27
- Medicenna Therapeutics Corp. adjustments for unrealised foreign exchange losses gains for the quarter ending 2023-03-31 was -1.07M CAD, a 985.95% decline year-over-year.
- Medicenna Therapeutics Corp. adjustments for unrealised foreign exchange losses gains for the quarter ending 2022-03-31 was 121.00K CAD, a 54.68% decline year-over-year.
- Medicenna Therapeutics Corp. adjustments for unrealised foreign exchange losses gains for the quarter ending 2021-03-31 was 267.00K CAD.
| Period end | Adjustments For Unrealised Foreign Exchange Losses Gains 3 month | Adjustments For Unrealised Foreign Exchange Losses Gains 12 month |
|---|---|---|
| 2023-03-31 | -1.07M CAD 20-F · filed 2023-06-27 | |
| 2022-03-31 | 121.00K CAD 20-F · filed 2023-06-27 | 121.00K CAD 20-F · filed 2022-06-22 |
| 2021-03-31 | 267.00K CAD 20-F · filed 2023-06-27 | 267.00K CAD 20-F · filed 2022-06-22 |
| 2020-03-31 | 62.00K CAD 20-F · filed 2022-06-22 |